Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial

Preclinical data demonstrate a key role for the epidermal growth factor receptor (EGFR) in the carcinogenesis of cutaneous squamous cell carcinomas (CSCCs). There are, however, limited data on the efficacy of EGFR inhibitors in incurable, recurrent, and/or metastatic CSCC.

http://ift.tt/2fAtIgM